中国卒中杂志 ›› 2023, Vol. 18 ›› Issue (02): 123-132.DOI: 10.3969/j.issn.1673-5765.2023.02.001
王文洁, 吕书玉, 侯叶叶, 毛佳文, 韩颖, 李子孝
收稿日期:
2023-02-02
出版日期:
2023-02-20
发布日期:
2023-02-20
通讯作者:
李子孝 lizixiao2008@hotmail.com
Received:
2023-02-02
Online:
2023-02-20
Published:
2023-02-20
王文洁, 吕书玉, 侯叶叶, 毛佳文, 韩颖, 李子孝. 缺血性脑血管病:回眸2022[J]. 中国卒中杂志, 2023, 18(02): 123-132.
WANG Wenjie, LYU Shuyu, HOU Yeye, MAO Jiawen, HAN Ying, LI Zixiao.
[1] XIONG Y Y,GU H Q,ZHAO X Q,et al. Clinical characteristics and in-hospital outcomes of varying definitions of minor stroke:from a large-scale nation-wide longitudinal registry[J]. Stroke,2021,52(4):1253-1258. [2] VON WEITZEL-MUDERSBACH P,ANDERSEN G,HUNDBORG H H,et al. Transient ischemic attack and minor stroke are the most common manifestations of acute cerebrovascular disease:a prospective,population-based study—the Aarhus TIA study[J]. Neuroepidemiology,2013,40(1):50-55. [3] ZHANG C Q,ZHAO X Q,WANG C X,et al. Prediction factors of recurrent ischemic events in one year after minor stroke[J/OL]. PLoS One,2015,10(3):e0120105[2023-01-30]. https://doi.org/10.1371/journal.pone.0120105. [4] HAO Q K,TAMPI M,O'DONNELL M,et al. Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack:systematic review and meta-analysis[J/OL]. BMJ(Clinical research ed),2018,363:k5108[2023-01-30]. https://doi.org/10.1136/bmj.k5108. [5] COUTTS S B,HILL M D,CAMPOS C R,et al. Recurrent events in transient ischemic attack and minor stroke:what events are happening and to which patients?[J]. Stroke,2008,39(9):2461-2466. [6] AMARENCO PIERRE,LAVALLÉE PHILIPPA C,LABREUCHE JULIEN,et al. One-year risk of stroke after transient ischemic attack or minor stroke[J]. N Engl J Med,2016,374(16):1533-1542. [7] AMARENCO P,LAVALLéE P C,MONTEIRO TAVARES L,et al. Five-year risk of stroke after TIA or minor ischemic stroke[J]. N Engl J Med,2018,378(23):2182-2190. [8] HOBEANU C,LAVALLéE P C,CHARLES H,et al. Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke:an international,prospective cohort study[J]. Lancet Neurol,2022,21(10):889-898. [9] CHRISTENSEN H. Long-term disability after transient ischaemic attack or minor stroke[J]. Lancet Neurol,2022,21(10):859-860. [10] FOSTER D S. Endarterectomy for asymptomatic carotid artery stenosis[J]. JAMA,1995,274(19):1505. [11] HALLIDAY A,HARRISON M,HAYTER E,et al. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis(ACST-1):a multicentre randomised trial[J]. Lancet,2010,376(9746):1074-1084. [12] AMARENCO P,BOGOUSSLAVSKY J,CALLAHAN A 3rd,et al. High-dose atorvastatin after stroke or transient ischemic attack[J]. N Engl J Med,2006,355(6):549-559. [13] ABBOTT A L. Medical(nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis:results of a systematic review and analysis[J/OL]. Stroke,2009,40(10):e573-e583[2023-01-30]. https://doi.org/10.1161/STROKEAHA.109.556068. [14] DEN HARTOG A G,ACHTERBERG S,MOLL F L,et al. Asymptomatic carotid artery stenosis and the risk of ischemic stroke according to subtype in patients with clinical manifest arterial disease[J]. Stroke,2013,44(4):1002-1007. [15] CHANG R W,TUCKER L Y,ROTHENBERG K A,et al. Incidence of ischemic stroke in patients with asymptomatic severe carotid stenosis without surgical intervention[J]. JAMA,2022,327(20):1974-1982. [16] STERPETTI A V,ARICI V,BOZZANI A. Ischemic stroke in patients with asymptomatic severe carotid stenosis without surgical intervention[J]. JAMA,2022,328(12):1255-1256. [17] HALLIDAY A,BULBULIA R,BONATI L H,et al. Second asymptomatic carotid surgery trial(ACST-2):a randomised comparison of carotid artery stenting versus carotid endarterectomy[J]. Lancet,2021,398(10305):1065-1073. [18] LEONARDI-BEE J,BATH P M,PHILLIPS S J,et al. Blood pressure and clinical outcomes in the international stroke trial[J]. Stroke,2002,33(5):1315-1320. [19] GREENBERG S M,ZIAI W C,CORDONNIER C,et al. 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage:a guideline from the American Heart Association/American Stroke Association[J/OL]. Stroke,2022,53(7):e282-e361[2023-01-30]. https://doi.org/10.1161/STR.0000000000000407. [20] WILLMOT M,GHADAMI A,WHYSALL B,et al. Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke[J]. Hypertension,2006,47(6):1209-1215. [21] WOODHOUSE L,SCUTT P,KRISHNAN K,et al. Effect of hyperacute administration(within 6 hours) of transdermal glyceryl trinitrate,a nitric oxide donor,on outcome after stroke:subgroup analysis of the efficacy of nitric oxide in stroke(ENOS) trial[J]. Stroke,2015,46(11):3194-3201. [22] RIGHT-2 INVESTIGATORS. Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke(RIGHT-2):an ambulance-based,randomised,sham-controlled,blinded,phase 3 trial[J]. Lancet,2019,393(10175):1009-1020. [23] VAN DEN BERG S,UNIKEN VENEMA S,REININK H,et al. Prehospital transdermal glyceryl trinitrate in patients with presumed acute stroke(MR ASAP):an ambulance-based,multicentre,randomised,open-label,blinded endpoint,phase 3 trial[J]. Lancet Neurol,2022,21(11):971-981. [24] MASOTTI L,GRIFONI E,DEI A,et al. Direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke:focus on real life studies[J]. J Thromb Thrombolysis,2019,47(2):292-300. [25] OLDGREN J,ASBERG S,HIJAZI Z,et al. Early versus delayed non-vitamin k antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation(TIMING):a registry-based randomized controlled noninferiority study[J]. Circulation,2022,146(14):1056-1066. [26] POWERS W J,RABINSTEIN A A,ACKERSON T,et al. Guidelines for the early management of patients with acute ischemic stroke:2019 update to the 2018 guidelines for the early management of acute ischemic stroke:a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J/OL]. Stroke,2019,50(12):e344-e418[2023-01-30]. https://doi.org/10.1161/STR.0000000000000211. [27] KAM W,HOLMES D N,HERNANDEZ A F,et al. Association of recent use of non-vitamin k antagonist oral anticoagulants with intracranial hemorrhage among patients with acute ischemic stroke treated with alteplase[J]. JAMA,2022,327(8):760-771. [28] KLEINDORFER D O,TOWFIGHI A,CHATURVEDI S,et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack:a guideline from the American Heart Association/American Stroke Association[J/OL]. Stroke,2021,52(7):e364-e467[2023-01-30]. https://doi.org/10.1161/STR.0000000000000375. [29] WANG Y J,WANG Y L,ZHAO X Q,et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med,2013,369(1):11-19. [30] JOHNSTON S C,EASTON J D,FARRANT M,et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA[J]. N Engl J Med,2018,379(3):215-225. [31] JOHNSTON S C,AMARENCO P,DENISON H,et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA[J]. N Engl J Med,2020,383(3):207-217. [32] SHARMA M,HART R G,CONNOLLY S J,et al. Stroke outcomes in the COMPASS trial[J]. Circulation,2019,139(9):1134-1145. [33] SHOAMANESH A,MUNDL H,SMITH E E,et al. Factor Ⅺa inhibition with asundexian after acute non-cardioembolic ischaemic stroke(PACIFIC-Stroke):an international,randomised,double-blind,placebo-controlled,phase 2b trial[J]. Lancet,2022,400(10357):997-1007. [34] PICCINI J P,CASO V,CONNOLLY S J,et al. Safety of the oral factor Ⅺa inhibitor asundexian compared with apixaban in patients with atrial fibrillation(PACIFIC-AF):a multicentre,randomised,double-blind,double-dummy,dose-finding phase 2 study[J]. Lancet,2022,399(10333):1383-1390. [35] GALE C,STATNIKOV Y,JAWAD S,et al. Neonatal brain injuries in England:population-based incidence derived from routinely recorded clinical data held in the National Neonatal Research Database[J/OL]. Arch Dis Child Fetal Neonatal Ed,2018,103(4):F301-F306[2023-01-30]. https://doi.org/10.1136/archdischild-2017-313707. [36] SORG A L,VON KRIES R,KLEMME M,et al. Incidence estimates of perinatal arterial ischemic stroke in preterm-and term-born infants:a national capture-recapture calculation corrected surveillance study[J]. Neonatology,2021,118(6):727-733. [37] GONZALEZ F,FERRIERO D M. Stem cells for perinatal stroke[J]. Lancet Neurol,2022,21(6):497-499. [38] WAGENAAR N,NIJBOER C H,VAN BEL F. Repair of neonatal brain injury:bringing stem cell-based therapy into clinical practice[J]. Dev Med Child Neurol,2017,59(10):997-1003. [39] BAAK LISANNE M,WAGENAAR NIENKE,VAN DER AA NIEK E et al. Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands(PASSIoN):a first-in-human,open-label intervention study[J]. Lancet Neurol,2022,21(6):528-536. [40] GONZALEZ F,FERRIERO D M. Stem cells for perinatal stroke[J]. Lancet Neurol,2022,21(6):497-499. [41] WINKLER E A,KIM C N,ROSS J M,et al. A single-cell atlas of the normal and malformed human brain vasculature[J/OL]. Science,2022,375(6584):eabi7377[2023-01-30]. https://doi.org/10.1126/science.abi7377. |
[1] | 霍晓川, 孙大鹏, 贾白雪, 高峰, 马宁, 莫大鹏, 缪中荣. 神经介入:回眸2022[J]. 中国卒中杂志, 2023, 18(02): 133-144. |
[2] | 王昱懿, 赵威, 段婉莹, 杨中华, 刘丽萍. 神经重症:回眸2022[J]. 中国卒中杂志, 2023, 18(02): 145-162. |
[3] | 程丝, 李昊.
卒中基因组学研究
[J]. 中国卒中杂志, 2023, 18(02): 163-167. |
[4] | 宗黎霞, 王献伟, 李子孝, 赵性泉, 刘丽萍, 李昊, 孟霞, 王伊龙, 王拥军.
血清丙氨酸转氨酶与急性缺血性脑血管病临床结局的相关性研究
[J]. 中国卒中杂志, 2023, 18(02): 185-193. |
[5] | 熊云云, 霍晓川, 贾白雪, 濮月华, 李光硕, 王利圆, 程丝, 郝曼均, 王拥军. 卒中:回眸2022[J]. 中国卒中杂志, 2023, 18(01): 1-16. |
[6] | 沈懿, 武剑. 缺血性卒中二级预防降压药物的选择[J]. 中国卒中杂志, 2023, 18(01): 54-59. |
[7] | 宋晓微, 桑振华, 侯朵朵, 陈文文, 张红亮, 郑卓肇, 赵锡海, 李睿, 武剑. 血压昼夜节律变化与颅内动脉粥样硬化斑块特征的相关性研究[J]. 中国卒中杂志, 2023, 18(01): 61-67. |
[8] | 蒲善宇, 周齐, 潘岳松. 我国脑血管病真实世界研究进展[J]. 中国卒中杂志, 2022, 17(12): 1289-1292. |
[9] | 冯玉婷, 刘芷含, 柴倩云, 罗慜婧, 高一城, 陶立元, 费宇彤. 真实世界研究中混杂因素和协变量控制——以脑血管病为例[J]. 中国卒中杂志, 2022, 17(12): 1304-1309. |
[10] | 金奥铭, 潘岳松. 倾向性评分法在脑血管病临床研究中的应用[J]. 中国卒中杂志, 2022, 17(12): 1310-1313. |
[11] | 吴娱倩, 张玉梅, 范小伟, 王安心, 逄文斌. 运动想象-动觉治疗对缺血性卒中患者手功能康复效果的研究[J]. 中国卒中杂志, 2022, 17(12): 1366-1371. |
[12] | 仇鑫, 李子孝. DNA甲基化与脑血管病[J]. 中国卒中杂志, 2022, 17(11): 1159-1161. |
[13] | 伊珞, 周宏宇, 仇鑫, 李子孝, 王拥军. 动脉粥样硬化性疾病的DNA甲基化改变[J]. 中国卒中杂志, 2022, 17(11): 1163-1170. |
[14] | 王誉博, 李子孝, 王拥军. 表观遗传学与缺血性卒中后氧化应激的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1171-1177. |
[15] | 崔凌云, 仇鑫, 周宏宇, 李子孝, 王拥军. DNA甲基化与2型糖尿病的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1183-1188. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||